论文部分内容阅读
目的分析血必净与胸腺肽联合治疗重症肺炎的效果。方法选取100例重症肺炎患者为研究对象,随机分组分为观察组与对照组,每组50例,观察组给予胸腺肽+血必净联合治疗,对照组给予单纯胸腺肽治疗。结果观察组患者治疗有效率为96.0%,明显高于对照组(86.0%,P<0.05);治疗后观察组患者白细胞计数和C-反应蛋白水平分别为(8.16±3.02)×109/L、(31.60±9.55)mg/L,对照组分别为(9.28±3.05)×109/L(37.79±10.87)mg/L,差异有统计学意义(P<0.05);治疗后观察组患者氧分压明显高于对照组,二氧化碳分压、心率低于对照组(P<0.05);治疗后观察组患者血管通透水平为(0.52±0.02)g/L,明显低于对照组的(0.58±0.01)g/L(P<0.05);观察组患者肺部顺应能力为(209.78±21.44)ml/cm H2O(1 cm H2O=0.098 k Pa),对照组为(201.57±20.58)ml/cm H2O,两组比较差异有统计学意义(P<0.05)。结论应用胸腺肽+血必净联合治疗重症肺炎效果明显,值得临床推广使用。
Objective To analyze the effect of Xuebijing combined with thymosin in the treatment of severe pneumonia. Methods 100 patients with severe pneumonia were selected as study subjects and randomly divided into observation group and control group, with 50 cases in each group. The observation group was given thymosin combined with Xuebijing and the control group was treated with thymosin alone. Results The effective rate of observation group was 96.0%, which was significantly higher than that of control group (86.0%, P <0.05). After treatment, the white blood cell count and C-reactive protein level of observation group were (8.16 ± 3.02) × 109 / L, (31.60 ± 9.55) mg / L in the control group and (9.28 ± 3.05) × 109 / L (37.79 ± 10.87) mg / L respectively in the control group, with significant difference (P <0.05) (0.52 ± 0.02) g / L in the observation group was significantly lower than that in the control group (0.58 ± 0.01, P <0.05) ) in the control group was (209.78 ± 21.44) ml / cm H2O (1 cm H2O = 0.098 kPa) and that in the control group was (201.57 ± 20.58) ml / cm H2O The difference between the two groups was statistically significant (P <0.05). Conclusion The application of thymosin combined with Xuebijing in the treatment of severe pneumonia has obvious effect and is worthy of clinical promotion.